Santacroce G, Gentile A, Soriano S, Novelli A, Lenti MV, Di Sabatino A, Glutathione
2025 GLP-1 Impacts Tell Us About CDMOs In 2026 By Louis Garguilo, Chief Editor, Outsourced Pharma When we began covering the nexus between GLP-1 drugs and CDMO capacity, there were two key questions: Could Novo Nordisk and Eli Lilly (and followers) keep up supply via internal and external manufacturing to meet exponential demand
Lead with the market context, not just the premium increase
PlexusDx serves all 50 states without requiring insurance, membership fees, or prior authorization
The wound-healing findings broaden the application bracket beyond the foundational longevity and anti-cancer streams